Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remternetug versus placebo in early Alzheimer's disease at risk for decline
jRCT2031240502Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Randomised, double-blind trial in Alzheimer's disease (AD) comparing Remternetug with Placebo (2 arms). Primary endpoint: Time to clinically meaningful progression as measured by Clinical Dementia Rating. Started Dec 2024; status: active, not recruiting.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031240502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240502.